Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.44 |
| ▸ | CTSV | O60911 | 7/20 | 0.44 |
| ▸ | CTSS | P25774 | 7/20 | 0.44 |
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.42 |
| ▸ | CTSB | P07858 | 4/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.41 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.41 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146114 | 1.00 | CTSL (0.44) | CTSLCTSVCTSSCTSKPSMB5 | |
| SCHEMBL3144809 | 0.90 | PIK3CA (0.41) | PSMB5NFKB1NFKB2RELAPSMB8 | |
| SCHEMBL3144799 | 0.90 | PIK3CA (0.41) | PSMB5NFKB1NFKB2RELAPSMB8 | |
| SCHEMBL3149873 | 0.88 | ALDH1A1 (0.41) | PSMB5NFKB1NFKB2RELAPSMB8 | |
| SCHEMBL3149826 | 0.88 | ALDH1A1 (0.41) | PSMB5NFKB1NFKB2RELAPSMB8 | |
| SCHEMBL3153536 | 0.87 | F2R (0.41) | PSMB5NFKB1NFKB2RELAPSMB8 | |
| SCHEMBL3153513 | 0.87 | F2R (0.41) | PSMB5NFKB1NFKB2RELAPSMB8 | |
| SCHEMBL3149564 | 0.87 | F2 (0.45) | CTSLPSMB5NFKB1NFKB2RELA | |
| SCHEMBL3149571 | 0.87 | F2 (0.45) | CTSLPSMB5NFKB1NFKB2RELA | |
| SCHEMBL1432414 | 0.87 | CTSL (0.44) | CTSLCTSVCTSSCTSKTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | CTSL 2316/4885CTSV 4079/4885CTSS 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.